|
| Press Releases |
|
 |
|
| Thursday, March 30, 2023 |
|
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
| Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. ("Maxpro", Nasdaq: JMAC). more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
| Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer. more info >> |
|
| Wednesday, January 12, 2022 |
|
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
| Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. more info >> |
|
| Tuesday, January 4, 2022 |
|
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. more info >> |
|
| Monday, November 22, 2021 |
|
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. more info >> |
|
| Friday, October 1, 2021 |
|
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
| Edison Oncology Holding Corp. ('Edison Oncology'), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ('Apollomics'), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. more info >> |
|
| Tuesday, August 10, 2021 |
|
|
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. more info >> |
|
| Thursday, May 20, 2021 |
|
|
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai. more info >> |
|
| Tuesday, March 9, 2021 |
|
|
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of K. Peony Yu, M.D. as Chief Medical Officer. Dr. Yu will assume the role on March 16, 2021. more info >> |
|
| Thursday, March 4, 2021 |
|
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. In February of this year, the two Phase 1 study sites were initiated. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The Future of Autonomous Fighters Is Coming To Rome
Nov 4, 2025 07:00 HKT/SGT
|
|
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S
Nov 3, 2025 23:00 HKT/SGT
|
|
|
Focus Graphite Receives Conditional Funding of up to $14.1M to Advance Canada's First Electrothermal Fluidized Purification Demonstration Plant
Nov 3, 2025 22:59 HKT/SGT
|
|
|
Founders Metals Announces $50,000,000 Strategic Investment by Gold Fields
Nov 3, 2025 20:09 HKT/SGT
|
|
|
Scam Encounters Every Four Days: Mexico's Financial Toll
Nov 3, 2025 20:00 HKT/SGT
|
|
|
Alltronics Completes Strategic Acquisition to Bolster R&D and Market Reach
Nov 3, 2025 16:13 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports 9M2025 Results
Nov 3, 2025 10:30 HKT/SGT
|
|
|
Star Plus Legend (6683.HK) Becomes a Strategic Shareholder of Galaxy
Nov 3, 2025 09:22 HKT/SGT
|
|
|
FWD Group reports strong new business growth
Nov 3, 2025 10:03 JST
|
|
|
Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Oct 31, 2025 0:45 JST
|
|
|
Sharp to Introduce AQUOS sense10 Smartphone
Oct 31, 2025 0:27 JST
|
|
|
Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Oct 31, 2025 0:07 JST
|
|
|
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile"
Oct 31, 2025 21:45 HKT/SGT
|
|
|
Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
Oct 31, 2025 19:56 HKT/SGT
|
|
|
Saudi Arabia Assumes Chairmanship of INTOSAI
Oct 31, 2025 19:45 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
